Exchange Traded Concepts LLC Makes New $944,000 Investment in Halozyme Therapeutics, Inc. $HALO

Exchange Traded Concepts LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 12,872 shares of the biopharmaceutical company’s stock, valued at approximately $944,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lansforsakringar Fondforvaltning AB publ increased its position in shares of Halozyme Therapeutics by 6.2% during the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 9,457 shares of the biopharmaceutical company’s stock valued at $603,000 after acquiring an additional 550 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Halozyme Therapeutics by 12.7% in the first quarter. The Manufacturers Life Insurance Company now owns 320,017 shares of the biopharmaceutical company’s stock worth $20,420,000 after purchasing an additional 36,147 shares during the last quarter. Pinnacle Wealth Planning Services Inc. bought a new position in Halozyme Therapeutics in the 1st quarter valued at $229,000. PDT Partners LLC increased its position in shares of Halozyme Therapeutics by 27.4% during the 1st quarter. PDT Partners LLC now owns 107,125 shares of the biopharmaceutical company’s stock valued at $6,836,000 after purchasing an additional 23,063 shares during the last quarter. Finally, EP Wealth Advisors LLC raised its stake in shares of Halozyme Therapeutics by 23.7% during the 1st quarter. EP Wealth Advisors LLC now owns 8,375 shares of the biopharmaceutical company’s stock worth $534,000 after purchasing an additional 1,606 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on HALO. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 6th. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Weiss Ratings restated a “hold (c+)” rating on shares of Halozyme Therapeutics in a research note on Monday, December 22nd. Leerink Partnrs upgraded Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group reissued a “sell” rating and set a $56.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $75.10.

Halozyme Therapeutics Trading Up 0.7%

Shares of HALO stock opened at $68.87 on Monday. The stock has a market capitalization of $8.10 billion, a price-to-earnings ratio of 14.50, a PEG ratio of 0.37 and a beta of 0.95. The company’s fifty day simple moving average is $67.34 and its two-hundred day simple moving average is $65.57. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $79.50. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. During the same period in the previous year, the business earned $1.27 earnings per share. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $55,285,726.65. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Cortney Caudill sold 4,263 shares of the business’s stock in a transaction that occurred on Saturday, November 1st. The shares were sold at an average price of $65.19, for a total transaction of $277,904.97. Following the transaction, the chief operating officer directly owned 12,737 shares of the company’s stock, valued at approximately $830,325.03. This represents a 25.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 85,661 shares of company stock valued at $6,036,837 in the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.